2096 Simcere Pharmaceutical Group Limited HKEX · China

Simcere Pharmaceutical Group (2096) news

Simcere Pharmaceutical Group Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 2096, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Simcere Pharmaceutical Group news

We have not published a story on Simcere Pharmaceutical Group yet. When there is news, it will appear here.

Questions about Simcere Pharmaceutical Group

What is the ticker symbol of Simcere Pharmaceutical Group?

Simcere Pharmaceutical Group Limited trades under the ticker 2096 on HKEX.

Where is Simcere Pharmaceutical Group listed?

Simcere Pharmaceutical Group Limited is listed on HKEX. Our directory also records these other listings: GETTEX:S2P.

Which country or territory is Simcere Pharmaceutical Group listed under?

Our directory records Simcere Pharmaceutical Group Limited under China.

What does Simcere Pharmaceutical Group do?

Our directory classifies Simcere Pharmaceutical Group Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Simcere Pharmaceutical Group?

The ISIN recorded for Simcere Pharmaceutical Group Limited is HK0000658531.

Does aibio.space cover Simcere Pharmaceutical Group?

aibio.space lists Simcere Pharmaceutical Group Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Simcere Pharmaceutical Group?

Companies in our directory listed in the same country and business area as Simcere Pharmaceutical Group: Shanghai Jiaoda Onlly Co., Shanghai Shenqi Pharmaceutical Investment Management Co., Sichuan Biokin Pharmaceutical Co., Kingchem (Liaoning) Life Science Co., Jiangsu Bioperfectus Technologies Co., Hangzhou Bio-Sincerity Pharma-Tech Co..

Investor discussion: Simcere Pharmaceutical Group

Members talk about Simcere Pharmaceutical Group (2096). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Simcere Pharmaceutical Group, newest first. Each line links the filing it comes from.

May 21, 2026Financings
Share or debt issue: (I) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES; (II) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (III) PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND; (IV) PROPOSED RE-APPOINTMENT OF AUDITORS; (V) PROPOSED AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION; AND (VI) NOTICE OF ANNUAL GENERAL MEETING. Source
Sep 10, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source
Sep 2, 2025Financings
Share or debt issue: PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source
Jun 22, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - AMENDMENT TO THE LICENSE AGREEMENT WITH IDORSIA. Source
May 22, 2025Financings
Share or debt issue: (I) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES; (II) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (III) PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND; AND (IV) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Simcere Pharmaceutical Group's own announcements, newest first. Each opens the full release on the newswire that carried it.

Sep 24, 2026HKEXnews
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2026
Sep 24, 2026HKEXnews
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2026
Sep 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF YINGMULE IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Sep 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSING AGREEMENT WITH ROCHE IN RELATION TO SIM0660
Aug 21, 2026HKEXnews
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME
Aug 20, 2026HKEXnews
CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Aug 20, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE
Aug 20, 2026HKEXnews
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jul 30, 2026HKEXnews
PROFIT ALERT
Jul 9, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - INCLUSION OF SANBEXIN (EDARAVONE AND DEXBORNEOL CONCENTRATED SOLUTION FOR INJECTION) INTO THE 2026 NATIONAL ESSENTIAL MEDICINES LIST
Jun 12, 2026HKEXnews
AMENDED AND RESTATED ARTICLES OF ASSOCIATION
Jun 12, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0689 (PD-1/VEGF BISPECIFIC ANTIBODY) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jun 12, 2026HKEXnews
(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2025
Jun 12, 2026HKEXnews
(I) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2026 (II) PAYMENT OF FINAL DIVIDEND AND (III) AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION
Jun 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH PRIMEGENX THERAPEUTICS IN RELATION TO PUMECITINIB GEL
May 21, 2026HKEXnews
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF CIRCULAR AND NOTICE OF ANNUAL GENERAL MEETING
May 21, 2026HKEXnews
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF CIRCULAR, NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM
May 21, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
May 21, 2026HKEXnews
(I) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES; (II) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (III) PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND; (IV) PROPOSED RE-APPOINTMENT OF AUDITORS; (V) PROPOSED AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION; AND (VI) NOTICE OF ANNUAL GENERAL MEETING
May 5, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0613 (LRRC15 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2096 on TradingView.

Listing details

Company: Simcere Pharmaceutical Group Limited
Ticker: 2096
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: HK0000658531
Other listed symbols: GETTEX:S2P
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction